RCM
JAZZ icon

Riverhead Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Riverhead Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$3.52M Buy
27,500
+3,240
+13% +$434K 0.13% 202
2019
Q2 		$3.46M Buy
24,260
+1,050
+5% +$141K 0.13% 224
2019
Q1 		$3.32M Buy
23,210
+9,420
+68% +$1.23M 0.13% 209
2018
Q4 		$1.71M Buy
13,790
+13,120
+1,958% +$1.95M 0.08% 312
2018
Q3 		$113K Buy
+670
New +$115K ﹤0.01% 1364

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Riverhead Capital Management's JAZZ Position: Q3 2019 in Review

Riverhead Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q3 2019, buying an estimated $434K and bringing the position to 27,500 shares worth $3.52M. The position accounts for 0.13% of the portfolio, ranked #202.

Riverhead Capital Management first reported a position in JAZZ in Q3 2018 and has held it in 5 quarters since. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

  • Riverhead Capital Management held 27,500 shares of Jazz Pharmaceuticals worth $3.52M as of Q3 2019.
  • Riverhead Capital Management bought 3,240 Jazz Pharmaceuticals shares in Q3 2019, an estimated $434K.
  • Jazz Pharmaceuticals made up 0.13% of Riverhead Capital Management's portfolio in Q3 2019, its #202 holding.
  • Riverhead Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2018 and has held it in 5 quarters since.
  • 406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.